Canertinib
Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM). By 2015, Pfizer had discontinued development of the drug. Canertinib has been reported as a substrate for the transporter protein OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. Canertinib is not an inhibitor of the OATP1B1 or OATP1B3 transporters.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Canertinib
Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM). By 2015, Pfizer had discontinued development of the drug. Canertinib has been reported as a substrate for the transporter protein OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. Canertinib is not an inhibitor of the OATP1B1 or OATP1B3 transporters.
has abstract
Canertinib (CI-1033) is an exp ...... TP1B1 or OATP1B3 transporters.
@en
alternative name
CI-1033; PD-183805
@en
IUPAC name
N-{4-(3-Chloro-4-fluoroanilino ...... quinazolin-6-yl}prop-2-enamide
@en
Wikipage page ID
33,217,762
page length (characters) of wiki page
Wikipage revision ID
1,021,479,987
Link from a Wikipage to another Wikipage
ImageFile
@en
imagesize
OtherNames
CI-1033; PD-183805
@en
PIN
N-{4--7-[3-propoxy]quinazolin-6-yl}prop-2-enamide
@en
Verifiedfields
changed
@en
verifiedrevid
460,016,047
Watchedfields
changed
@en
wikiPageUsesTemplate
subject
hypernym
comment
Canertinib (CI-1033) is an exp ...... TP1B1 or OATP1B3 transporters.
@en
label
Canertinib
@en